tirzepatide cardiovascular outcomes trial 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT found that was noninferior to dulaglutide for major events (12.2% vs 13.1%; HR 0.92). What Cardiovascular and Cerebrovascular Outcomes Risk

Instead of looking only for overt disease, the approach may include a deeper look at gut health, microbiome balance, nutrient deficiencies, hormone patterns, inflammation markers, environmental toxin exposure, and the interplay between them

A short intake questionnaire cannot replace a comprehensive medical assessment that includes health history review, medication reconciliation, laboratory evaluation, and cardiovascular risk screening

They've got a prescription for a compounded drug that can't be filled anymore, says Alliance for Pharmacy Compounding CEO Scott Brunner

PMID 11462772

Depends on your research question